Perindopril arginine: Benefits of a new salt of the ACE inhibitor perindopril

Current Medical Research and Opinion

Volumn 23, Issue 5, 2007, Pages 953-960

  Telejko, Elwira ^a,b  

^a Studium Kszta cenia Podyplomowego   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acceptability; Bioequivalence; L arginine; Perindopril; Shelf life; Stability

Indexed keywords

AMLODIPINE; ATENOLOL; BENDROFLUMETHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCURONIDE; PERINDOPRIL; PERINDOPRIL ARGININE; PERINDOPRIL TERT BUTYLAMINE; PERINDOPRILAT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ASTHENIA; BACKACHE; BIOEQUIVALENCE; COMBINATION CHEMOTHERAPY; CONSUMER; COUGHING; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PACKAGING; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; MONOTHERAPY; NAUSEA; NONHUMAN; SHELF LIFE; SHORT SURVEY; VOMITING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLIMATE; DRUG EVALUATION; DRUG PACKAGING; DRUG STABILITY; GEOGRAPHY; HUMANS; MODELS, BIOLOGICAL; PATIENT ACCEPTANCE OF HEALTH CARE; PERINDOPRIL; RISK ASSESSMENT; THERAPEUTIC EQUIVALENCY;

EID: 34249112256     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X182158     Document Type: Short Survey

References (30)

1. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
2. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
3. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006;166:659-66
4. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
5. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45
6. Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 2004;20:1559-69
7. Morishita T, Tsutsui M, Shimokawa H, et al. Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol 2002;88:100-7
8. Su JB, Barbe F, Crozatier B, et al. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol 1999;34:700-10
9. Devissaguet JP, Ammoury N, Devissaguet M, Perret L. Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundam Clin Pharmacol 1990;4:175-89
10. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005;3:15-29
11. Physicians' Desk Reference, 55th edn. Montvale, NJ: Medical Economics Company, 2001
12. Julius S, Cohn JN, Neutel J, et al. Antihypertensive utility of Perindopril in a large, general practice-based clinical trial. J Clin Hypertens (Greenwich) 2004;6:10-17
13. Poggi L, Renucci JF, Denolle T. Treatment of essential hypertension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril. Can J Cardiol 1994;10(Suppl D):21-24D
14. Lechat P, Garnham SP, Desche P, Bounhoure JP. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J 1993;126:798-806
15. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. BMJ 1991;302:210-16
16. Ceconi C, Fox K, Remme WJ, et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2006;doi:10.1016/j.cardiores.2006.10.021
17. National Institute for Health and Clinical Excellence (NICE) - British Hypertension Society (BHS). Hypertension: management of hypertension in adults in primary care. Available from www.nice.org.uk/CG034guidance. [Accessed 12 July 2006]
18. Yoshinaga K, Saruta T, Abe K, et al. Clinical evaluation of monotherapy with perindopril, an ACE inhibitor, in the treatment of essential hypertension: double-blind parallel comparison with enalapril. J Clin Ther Medicines 1997;13:4259-97
19. Telejko E. Stability of tablets and efficiency and safety of drug use in various situations [in Polish]. Farmacja Polska 2006;62:381-88
20. ICH Steering Committee. Quality guidelines. Available from www.ich.org/cache/compo/363-272-1.html. [Accessed 9 May 2006]
21. Dietz R, Feilner K, Gerst F, Grimm W. Drug stability testing. Classification of countries according to climatic zone. Drugs made in Germany 1993;36:99-103
22. Al Omari MM, Abdelah MK, Badwan AA, Jaber AM. Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations. J Pharm Biomed Anal 2001;25:893-902
23. al Zein H, Riad LE, Abd-Elbary A. Effect of packaging and storage on the stability of carbamazepine tablets. Drug Dev Ind Pharm 1999;25:223-7
24. Reynolds JM, Rogers DH. Adjusting dissolution specifications for the variability induced by storage conditions. J Biopharm Stat 2000;10:425-31
25. Stanisz B. Kinetics of degradation of quinapril hydrochloride in tablets. Pharmazie 2003;58:249-51
26. Stanisz B. Kinetics of degradation of enalapril maleate in dosage forms. Acta Pol Pharm 2004;61:415-18
27. Risha PG, Vervaet C, Vergote G, et al. Drug formulations intended for the global market should be tested for stability under tropical climatic conditions. Eur J Clin Pharmacol 2003;59:135-41
28. Wu Y, Fassihi R. Stability of metronidazole, tetracycline HCl and famotidine alone and in combination. Int J Pharm 2005;290:1-13
29. Mohamad H, Aiache JM, Renoux R, et al. Study on the biopharmaceutical stability of medicines IV. Application to tetracycline hydrochloride capsules. In vivo study. STP Pharm 1987;3:407-11
30. Nazerali H, Muchemwa T, Hogerzeil HV. Stability of Essential Medicines in Tropical Climates: Zimbabwe. WHO/DAP/94.16. Geneva, Switzerland: WHO 1996